約80%的晚期卵巢癌患者會在2至3年內復發。二次腫瘤減積手術對完全切除機會較高的特定患者有益。二次間隔手術能否用於復發時仍屬未知。
適應症：Recurrent Ovarian Carcinoma
收案條件
納入條件
- Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma
- \>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / or PARPi, at primary setting
- Platinum-free interval should be \>=6 months from the last dose of platinum-based chemotherapy
- Upfront SCR not feasible
- Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment.
- Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.
排除條件
- Non-epithelial or borderline tumors are excluded
- Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded.
- Patients using more than one line of chemotherapy are excluded.
- Patients who have platinum-resistant or refractory recurrence are excluded.
- Patients having second relapse or beyond are excluded.
- Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。